Under construction – not a live service
Sign in
Taking people in GermanyPhase 1

Testing ABO21009 safety in healthy people and rheumatoid arthritis patients

Tests ABO21009, a new medicine, in adults with rheumatoid arthritis and healthy volunteers.

Key facts

Who runs it
Aboleris Holdco
Where
Erlangen and Frankfurt Am Main, GermanySee the 2 sitesAlso in 2 other countries, 3 sites
Registry title
A placebo-controlled, single-blind, phase I study in healthy volunteers and patients with Rheumatoid Arthritis with ABO21009
Status
Recruiting
Phase
Phase 1
People taking part
78 people, planned
Started
31 Jan 2025
Expected to end
30 Sept 2027
Type of study
Interventional
Record updated
15 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for healthy volunteers and people with rheumatoid arthritis to test ABO21009 against a placebo.

Age
18 years or older
Sex
All sexes can join

Where in Germany

Also in 2 other countries, 3 sites

  • Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
  • Fraunhofer Institute For Translational Medicine And Pharmacology ITMPFrankfurt Am Main, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Testing ABO21009 safety in healthy people and rheumatoid arthritis patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
15 June 2026